Personalized Low-Dose Aspirin Use for Cancer Prevention in Older Adults
Highlight
This secondary analysis of the ASPREE randomized clinical trial identifies heterogeneous effects of low-dose aspirin (LDA) for cancer prevention among older adults. It pinpoints clonal hematopoiesis of indeterminate potential (CHIP) as the strongest individual predictor of aspirin benefit. Personalized treatment prediction models enabled improved 5-year absolute cancer risk reduction versus a universal aspirin approach.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.